Vincent T. Ma

Dr. Vincent T. Ma

Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JYJiali Yu
Jiali Yu
MGMichael Green
Michael Green
SLShasha Li
Shasha Li
YSYilun Sun
Yilun Sun
SJSara N. Journey
Sara N. Journey
WZWeiping Zou
Weiping Zou

20 March 2013 in Physiologia Plantarum
Verified
Journal Article
Closed access
PDF file
SLSong Luhua
Song Luhua
AHAlicia Hegie
Alicia Hegie
Nobuhiro SuzukiNobuhiro Suzuki
Nobuhiro Suzuki
ESElena Shulaev
Elena Shulaev
XLXiaozhong Luo
Xiaozhong Luo
Ron MittlerRon Mittler
Ron Mittler

4 May 2012 in The Plant Cell
Verified
Journal Article
Open access
PDF file
RNRachel Nechushtai
Rachel Nechushtai
ACAndrea R. Conlan
Andrea R. Conlan
YHYael Harir
Yael Harir
LSLuhua Song
Luhua Song
OYOhad Yogev
Ohad Yogev
Ron MittlerRon Mittler
Ron Mittler
The NEET family is a newly discovered group of proteins involved in a diverse array of biological processes, including autophagy, apoptosis, aging, diabetes, and reactive oxygen homeostasis. They form a novel structure, the NEET fold, in which two protomers intertwine to form a two-domain motif, a cap, and a unique redox-active labile 2Fe-2S cluster binding domain. To accelerate the functional study of NEET proteins, as well as to examine whether they have an evolutionarily conserved role, we identified and characterized a plant NEET protein. Here, we show that the Arabidopsis thaliana At5g51720 protein (At-NEET) displays biochemical, structural, and biophysical characteristics of a NEET protein. Phenotypic characterization of At-NEET revealed a key role for this protein in plant development, senescence, reactive oxygen homeostasis, and Fe metabolism. A role in Fe metabolism was further supported by biochemical and cell biology studies of At-NEET in plant and mammalian cells, as well as mutational analysis of its cluster binding domain. Our findings support the hypothesis that NEET proteins have an ancient role in cells associated with Fe metabolism.

5 February 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KHKelly L. Harms
Kelly L. Harms
LZLili Zhao
Lili Zhao
BJBryan Johnson
Bryan Johnson
XWXiaoming Wang
Xiaoming Wang
SCShannon Carskadon
Shannon Carskadon
PHPaul Harms
Paul Harms
Purpose: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma that can be divided into two classes: virus-positive (VP) MCC, associated with oncogenic Merkel cell polyomavirus (MCPyV); and virus-negative (VN) MCC, associated with photodamage. Experimental Design: We classified 346 MCC tumors from 300 patients for MCPyV using a combination of IHC, ISH, and qPCR assays. In a subset of tumors, we profiled mutation status and expression of cancer-relevant genes. MCPyV and molecular profiling results were correlated with disease-specific outcomes. Potential prognostic biomarkers were further validated by IHC. Results: A total of 177 tumors were classified as VP-MCC, 151 tumors were VN-MCC, and 17 tumors were indeterminate. MCPyV positivity in primary tumors was associated with longer disease-specific and recurrence-free survival in univariate analysis, and in multivariate analysis incorporating age, sex, immune status, and stage at presentation. Prioritized oncogene or tumor suppressor mutations were frequent in VN-MCC but rare in VP-MCC. TP53 mutation developed with recurrence in one VP-MCC case. Importantly, for the first time we find that VP-MCC and VN-MCC display distinct sets of prognostic molecular biomarkers. For VP-MCC, shorter survival was associated with decreased expression of immune markers including granzyme and IDO1. For VN-MCC, shorter survival correlated with high expression of several genes including UBE2C. Conclusions: MCPyV status is an independent prognostic factor for MCC. Features of the tumor genome, transcriptome, and microenvironment may modify prognosis in a manner specific to viral status. MCPyV status has clinicopathologic significance and allows for identification of additional prognostic subgroups.

12 February 2018 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
APAmrita Padda
Amrita Padda
ESElena Schiopu
Elena Schiopu
JSJustin Sovich
Justin Sovich
Vincent T. MaVincent T. Ma
Vincent T. Ma
AAAjjai Alva
Ajjai Alva
LFLeslie Fecher
Leslie Fecher
Background Immune check point inhibitors (ICIs) have emerged as a new therapeutic paradigm for a variety of malignancies including metastatic melanoma. As the use of ICIs expand, immune-mediated adverse events are becoming a common occurrence. Case presentation We describe the first reported patient with small vessel vasculitis, manifested by digital ischemia, following treatment with high dose Ipilimumab for resected stage IIIB/C melanoma. This patient received high dose steroids, five-day intravenous (IV) Epoprostenol protocol, botulinum toxin injections, and Rituximab 375 mg/m2 weekly for four cycles. With this treatment regimen, the digital ischemia did not progress proximally, but she did require multiple distal digit amputations about six months after the onset of her symptoms. Conclusions Prompt identification and management of immune related adverse events (IRAEs) are critical to optimal patient management. This patient’s vasculitis did not reverse, but was likely halted and stabilized with multiple immunosuppressive medications.

13 April 2022 in Immunotherapy
Verified
Journal Article
Closed access
Vincent T. MaVincent T. Ma
Vincent T. Ma
CLChristopher D Lao
Christopher D Lao
LFLeslie A Fecher
Leslie A Fecher
ESElena Schiopu
Elena Schiopu
Immune-related adverse events (irAEs) are a major concern when treating cancer patients with immune checkpoint inhibitor (ICI) therapy. Selecting the most appropriate management of irAEs remains an... Plain language summary Immune-related adverse events (irAEs) are unwanted side effects commonly seen in cancer patients treated with immunotherapy. A frequently underreported irAE is inflammation o... Tweetable abstract Successful use of secukinumab in two cases of inflammatory arthropathy occurring in melanoma patients treated with immune checkpoint inhibitors.